Description

NSI 189 Phosphate Liquid

Introduction

NSI 189 Phosphate is a meticulously developed research product explicitly crafted for scientific exploration, emphasizing its application in research and refraining from any mention of human consumption. This compound serves as a valuable tool for researchers investigating its unique properties and potential benefits in various research domains.

Key Characteristics

NSI 189 Phosphate is a derivative of benzylpiperazine and has been of interest in the scientific community for its potential neuroregenerative properties. Recognized for its impact on neurogenesis, it has become a focus of research in the field of neuroscience.

Research Applications

NSI 189 Phosphate finds diverse applications in research domains, offering researchers a tool to explore its potential benefits. Its applications extend to investigations into major depressive disorder (MDD), ischemic stroke, and diabetic neuropathy.

Research Benefits

NSI 189 Phosphate and Major Depressive Disorder (MDD)

Studies suggest that NSI 189 Phosphate may have potential applications in addressing major depressive disorder. Research in this domain aims to understand its mechanisms of action and potential therapeutic applications in the context of depressive disorders.

NSI 189 Phosphate and Ischemic Stroke

Preliminary research indicates that NSI 189 Phosphate may have neuroprotective effects, particularly in the context of ischemic stroke. Investigations into its effects on neuronal survival and recovery contribute to understanding its potential applications in stroke-related conditions.

NSI 189 Phosphate and Diabetic Neuropathy

Research suggests that NSI 189 Phosphate may have implications for diabetic neuropathy, potentially influencing nerve function and regeneration. Studies exploring its effects on diabetic neuropathy-related parameters contribute to understanding its potential applications in neuropathic conditions.

Summary

NSI 189 Phosphate, developed exclusively for research purposes, provides researchers with a unique avenue for investigating its potential benefits in major depressive disorder, ischemic stroke, and diabetic neuropathy. The distinctive characteristics of NSI 189 Phosphate make it a promising subject for further exploration in neuroscientific and neuropsychiatric research.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon the finalization of your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer contentment stands as our paramount concern. Should you find any dissatisfaction with the product received, kindly contact us at 419-707-5450 or email our support team at [email protected].

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Fava M, Johe K, Ereshefsky L, Gertsik LG, English BA, Bilello JA, Thurmond LM, Johnstone J, Dickerson BC, Makris N, Hoeppner BB, Flynn M, Mischoulon D, Kinrys G, Freeman MP. A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Mol Psychiatry. 2016 Oct;21(10):1372-80. doi: 10.1038/mp.2015.178. Epub 2015 Dec 8. Erratum in: Mol Psychiatry. 2016 Oct;21(10):1483-4. PMID: 26643541; PMCID: PMC5030464. [Read More].
2. Tajiri, N, Quach, DM, Kaneko, Y, et al. NSI-189, a small molecule with neurogenic properties, exerts behavioral, and neurostructural benefits in stroke rats. J Cell Physiol. 2017; 232: 2731–2740. https://doi.org/10.1002/jcp.25847. [Read More].
3. Jolivalt CG, Marquez A, Quach D, Navarro Diaz MC, Anaya C, Kifle B, Muttalib N, Sanchez G, Guernsey L, Hefferan M, Smith DR, Fernyhough P, Johe K, Calcutt NA. Amelioration of Both Central and Peripheral Neuropathy in Mouse Models of Type 1 and Type 2 Diabetes by the Neurogenic Molecule NSI-189. Diabetes. 2019 Nov;68(11):2143-2154. doi: 10.2337/db19-0271. Epub 2019 Sep 6. PMID: 31492662; PMCID: PMC6804627. [Read More].